Clinical Trial DRUG 0761-009
- Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Principal Investigator
- Adam M Petrich
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG 0761-009
- The main purpose of this study is to determine if KW-0761, an investigational drug (has not been approved by the U.S. food and Drug Administration [FDA]), will work against adult T-cell leukemia-lymphoma (ATL)that has failed to respond to other treatments, and to evaluate its side effects.
- Antibodies are proteins which the immune system, your body’s defense system, uses to recognize foreign or unwanted material, such as infection or some cancers. Antibodies are used to try to destroy cancer cells while causing little harm to normal cells. The cancer cells of many patients with T-cell leukemia-lymphoma contain a protein called CCR4. KW-0761 is an antibody that finds T-cells that have a protein called CCR4 on their surface and attempts to destroy them.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have relapsed(cancer returned) or refractory(cancer did not respond to treatment)adult T-cell Leukemia Lymphoma (ATL)after at least one systemic (whole body) therapy regimen (cycle).
- Description of Treatment
- Participants will be assigned by chance (like flipping a coin) using a computer program into one of two groups. One group identified as the Investigator's choice group will receive one of 3 treatments that the doctor decides would best treat the participant's cancer. The choices are pralatrexate (also known as Folotyn; this drug is currently only available in the US), gemcitabine and oxaliplatin (also known as GemOx) or a 3 drug regimen known as DHAP(dexamethasone, cisplatin and cytarabine). The other group referred to as the KW-0761 group will receive the study drug. All of the treatments will be given by infusion (into a vein)and dependent upon what drug a participant is receiving, a cycle (one treatment course) can be anywhere from 4 to 22 days. Participants will continue receiving treatment as long as their cancer responds to the treatment or until the doctor feels it is in their best interest to stop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Adam M Petrich
- A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
- An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
- Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
- Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas
- A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
- A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
last updated: 01-Oct-14 05:19 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.